Active Ingredient(s): Fluciclovine
FDA Approved: * May 27, 2016
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Axumin Overview

Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (anti-3[18F] FACBC),[1][2] or as Axumin (brand name), is a diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels.[3][4] Contents 1 Background 2 Mechanism 3 Marketing 4 References 5 External links Background Most...

Read more Axumin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Axumin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 335-8200 Mbq/ml (9-221 Mci/ml)
  • Solution: 9-221mci/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Axumin: (1 result)

Sorted by National Drug Code
  • 69932-001 Axumin 221 mci/Ml Intravenous Injection, Solution by Blue Earth Diagnostics

Other drugs which contain Fluciclovine or a similar ingredient: (1 result)